AbbVie Inc


SKU: ABBV-1 Category:


AbbVie Inc.: Acquisition of Landos Biopharma to Enhance Autoimmune Disease Treatments & Other Major Developments


Leading pharmaceutical company AbbVie Inc. has outperformed expectations in its first quarter 2024 results. The financial results and current business outlook reflect the strength and momentum of AbbVie’s diversified pharmaceutical portfolio, which is projected to have long-term growth prospects. The company reported adjusted earnings per share of $2.31 and total net revenues of $12.3 billion, exceeding expectations by $400 million. This overperformance was driven by the company’s ex-Humira growth platform, which recorded revenue growth of more than 15% this quarter.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!